Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials

We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once‐daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmun...

Descripción completa

Detalles Bibliográficos
Autores principales: Vora, J., Seufert, J., Solberg, H., Kinduryte, O., Johansen, T., Hollander, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067686/
https://www.ncbi.nlm.nih.gov/pubmed/26663320
http://dx.doi.org/10.1111/dom.12621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067686/
https://www.ncbi.nlm.nih.gov/pubmed/26663320
http://dx.doi.org/10.1111/dom.12621

Ejemplares similares